AI-Generated Filing Summaries

Lianhe Sowell International Group Ltd cancelled its extraordinary general meeting of shareholders originally scheduled for March 25, 2026, at 10:00 p.m. Eastern Time (March 26, 2026, at 10:00 a.m. Beijing time). The Board approved the cancellation on March 22, 2026, with notice to be sent or made available to shareholders on or about March 24, 2026.

Sturm, Ruger & Company, Inc. launched ruger.com/proxy2026 on March 24, 2026, hosting materials for its 2026 Annual Meeting of Stockholders, including information on its refreshed Board with five new directors, capital stewardship, shareholder returns, performance, and strategic direction. The press release is Exhibit 99.1 and website materials are Exhibit 99.2.

PMGC Holdings Inc. announced that its wholly owned subsidiary, SVM Machining, Inc. dba Silicon Valley Manufacturing, has completed ITAR registration and is in compliance with ITAR. This enables SVM to pursue U.S. defense and aerospace programs requiring export-control compliance and enhances its eligibility as a supplier to Tier 1 defense contractors.

Vertiv Holdings Co. announced that one of its wholly-owned subsidiaries executed a definitive agreement to acquire ThermoKey S.p.A., a provider of heat rejection and heat-exchange technologies. The acquisition is expected to expand Vertiv's thermal management portfolio and manufacturing in EMEA for AI data centers and is anticipated to close in Q2 2026, subject to customary conditions including regulatory approvals.

Earth Science Tech, Inc. issued a press release on March 24, 2026, announcing the launch of MyOnlineConsultation.com through MOCTeledoc, LLC, finalizing a vertically integrated telehealth and pharmacy ecosystem that is cash-flow-positive post-beta. The platform integrates with ETST's compounding pharmacies RxCompound and Mister Meds, and is expected to become a significant revenue stream alongside divisions generating $25.9 million in revenue for the nine months ended December 31, 2025.

Dollar General Corporation's Board approved Jerry W. “JJ” Fleeman, Jr. to succeed Todd J. Vasos as CEO effective January 1, 2027, with Fleeman joining the Board and Vasos serving as Senior Advisor through April 2, 2027 while remaining a Board member. Employment and transition agreements outline compensation terms including base salaries, bonuses, equity awards, and severance provisions.

Keysight Technologies, Inc. held its Annual Meeting of Stockholders on March 19, 2026, with 155,848,414 shares (91% quorum) present. Stockholders elected three directors, ratified PricewaterhouseCoopers LLP as auditors for fiscal year 2026, approved named executive officer compensation, declassified the Board of Directors, and approved a stockholder proposal for special shareholder meetings.

BioAge Labs, Inc. (BIOA) reported collaboration revenue of $9.0 million for FY 2025, ending December 31, 2025, primarily from partnerships. The company posted a net loss of $80.6 million, widening from prior periods due to elevated operating expenses totaling $101.8 million, with research and development at $74.0 million and general and administrative at $27.8 million, resulting in a loss from operations of $92.8 million. This was partially offset by $12.2 million in other income (expense), net, including $13.1 million in interest and other income. Basic and diluted net loss per share was $2.00 on 35.9 million weighted-average shares. Balance sheet remains solid with total assets of $294.9 million, including $188.9 million in cash and equivalents and $92.2 million in current marketable securities, yielding total current assets of $286.8 million and stockholders' equity of $272.1 million. Cash flows reflected heavy investment: operating activities used $81.6 million, investing $95.2 million (including $154.7 million marketable securities purchases), financing provided $11.5 million (notably $17.2 million from at-the-market offerings), netting a $165.5 million decrease in cash to $25.0 million end balance. Forward-looking, BioAge advances BGE-102 NLRP3 inhibitor with Phase 1 completion H1 2026, Phase 2a in obesity/elevated hsCRP H1 2026 (results YE 2026), and DME trial mid-2026; APJ agonists IND YE 2026. Cash runway supports through 2029, focusing on cardiometabolic pipeline amid high R&D burn.

Silexion Therapeutics Corp. received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. This regulatory milestone advances SIL204 into clinical-stage development as a next-generation RNAi therapy targeting KRAS mutations present in over 90% of pancreatic cancers.

Silexion Therapeutics Corp. received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. This regulatory milestone advances SIL204 into clinical-stage development as a next-generation RNAi therapy targeting KRAS mutations present in over 90% of pancreatic cancers.

BioAge Labs, Inc. announced full year 2025 financial results with $9.0 million collaboration revenue, $73.9 million R&D expenses, $27.8 million G&A expenses, and $80.6 million net loss. Highlights include positive interim Phase 1 data for BGE-102 demonstrating 86% median hsCRP reduction and plans for Phase 2a trials, plus $132.3 million follow-on offering extending cash runway through 2029.

Table Trac, Inc. (TBTC) reported FY 2025 revenues of $11.0 million, a 1% decline from $11.2 million in 2024, primarily due to lower system sales of $2.9 million (down 29% YoY), offset by maintenance revenue growth to $6.2 million (up 14% YoY) and service revenue up 13% to $1.9 million. Gross profit rose 3% to $8.2 million, with margins expanding to 73.9% from 70.7%, driven by reduced cost of sales to $2.9 million from $3.3 million. Operating income was $1.6 million (down 7% YoY), while net income increased 3% to $1.6 million, or $0.35 per basic share (up from $0.34). Cash from operations was $1.8 million, bolstered by investing activities yielding $4.5 million mainly from $4.6 million in short-term investment proceeds, resulting in a $6.0 million net cash increase; cash and equivalents ended at $8.2 million. Total assets stood at $14.4 million, with stockholders' equity at $12.8 million and minimal liabilities of $1.5 million, no debt outstanding. The company serves 115 casino operators across over 300 casinos, adding eight new customers in 2025, with 93.7% revenues from the U.S. Strong liquidity supports dividends ($371K paid) and growth amid competitive gaming industry.

Silver Pegasus Acquisition Corp Rights. (SPEG), a Cayman Islands blank check company formed on June 5, 2024, reported net income of $3K for FY 2025 ended December 31, 2025, compared to a net loss of $50K for the stub period from inception through December 31, 2024. The modest profit resulted from $2.1M interest earned on marketable securities held in the Trust Account, yielding total other income net of $385K, which offset a $382K operating loss, $1.6M loss on derivative liability, and $111K IPO transaction costs. No operating revenues were generated, as activities were limited to IPO completion and business combination search. On July 16, 2025, the Company raised $115M gross proceeds from 11,500,000 units at $10 per unit (including over-allotment), plus $3.2M from private placement warrants. Balance sheet reflects $117.6M total assets, with $117.1M in Trust Account at ~$10.18 per redeemable share and $379K cash outside trust. Liabilities total $8.5M, including $4.0M deferred underwriting fee, with shareholders' deficit of -$7.9M. Net cash used in operations was -$413K, offset by financing inflows. The Company focuses on technology/semiconductor targets with $200-500M enterprise value, targeting completion by January 16, 2027, amid going concern doubts due to liquidity needs.

Silver Pegasus Acquisition Corp Rights. (SPEG), a Cayman Islands blank check company formed on June 5, 2024, reported net income of $3K for FY 2025 ended December 31, 2025, compared to a net loss of $50K for the stub period from inception through December 31, 2024. The modest profit resulted from $2.1M interest earned on marketable securities held in the Trust Account, yielding total other income net of $385K, which offset a $382K operating loss, $1.6M loss on derivative liability, and $111K IPO transaction costs. No operating revenues were generated, as activities were limited to IPO completion and business combination search. On July 16, 2025, the Company raised $115M gross proceeds from 11,500,000 units at $10 per unit (including over-allotment), plus $3.2M from private placement warrants. Balance sheet reflects $117.6M total assets, with $117.1M in Trust Account at ~$10.18 per redeemable share and $379K cash outside trust. Liabilities total $8.5M, including $4.0M deferred underwriting fee, with shareholders' deficit of -$7.9M. Net cash used in operations was -$413K, offset by financing inflows. The Company focuses on technology/semiconductor targets with $200-500M enterprise value, targeting completion by January 16, 2027, amid going concern doubts due to liquidity needs.

WeRide Inc. repurchased 213,100 Class A Ordinary Shares on 24 March 2026 via on-market purchases on the Stock Exchange of Hong Kong at prices between HKD 17.53 and HKD 17.55 per share, for an aggregate HKD 3,739,891. The shares are held as treasury shares, reducing issued shares excluding treasury shares from 972,508,041 to 972,294,941 as at 24 March 2026.

Eni approved 2025 consolidated financial statements with €2,608 million net profit attributable to shareholders and parent company draft statements with €4,429 million profit, convened annual shareholders' meeting on May 6, 2026, initiated Plenitude deconsolidation via €1.5 billion capital increase at €10.75 billion pre-money valuation, and proposed new share buyback program.

Eni approved 2025 consolidated financial statements with €2,608 million net profit attributable to shareholders and parent company draft statements with €4,429 million profit, convened annual shareholders' meeting on May 6, 2026, initiated Plenitude deconsolidation via €1.5 billion capital increase at €10.75 billion pre-money valuation, and proposed new share buyback program.

InterContinental Hotels Group PLC has made available to shareholders the Notice of 2026 Annual General Meeting and Form of Proxy, submitted to the UK Listing Authority. The AGM is scheduled for 11:00 BST on Thursday 7 May 2026 at InterContinental London Park Lane, One Hamilton Place, Park Lane, London W1J 7QY, with a live webcast available but no remote voting or live Q&A.

The Federal Home Loan Bank of Pittsburgh disclosed under Item 2.03 the issuance of consolidated obligation bonds for which it is the primary obligor, as detailed in Schedule A of Exhibit 99.1. These debt securities, consisting of bonds sold in capital markets, represent most of the FHLBank's funding and are joint and several obligations of the eleven Federal Home Loan Banks, backed solely by their resources.

Actelis Networks, Inc. entered into a binding term sheet to acquire 100% of Exaware Ltd., an Israel-based provider of high-throughput routing and switching platforms, in an all-stock transaction. The deal positions Actelis to enter the AI-driven data center networking market with a unified networking platform, subject to definitive agreement and closing by May 7, 2026.

Audax Private Credit Fund, LLC sold 456,132.001 common shares on February 1, 2026, at a purchase price of $25.212 per share for total consideration of $11.5 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D or S. As of January 31, 2026, NAV per common share was $25.212, aggregate NAV was $515.6 million, investment portfolio fair value was $957.3 million, and principal debt outstanding was $481.0 million with a 0.93x debt-to-equity ratio.

Banco Latinoamericano de Comercio Exterior, S.A. filed a Form 6-K on 2026-03-24 furnishing Exhibit 99.1, consisting of BladexID2026Presentation.pdf. The exhibit contains the company's Investor Day 2026 presentation materials.

ASP Isotopes Inc. announced that a UK subsidiary of its wholly-owned subsidiary Quantum Leap Energy LLC has commenced a strategic collaboration with the University of Bristol for the design of a state-of-the-art lithium laser research facility in the UK. This collaboration involves a four-month initial phase for feasibility study and design work, marking a milestone in QLE's strategy to meet demand for advanced nuclear fuels.

Benchmark 2021-B24 Mortgage Trust's 10-K filing for fiscal year ended December 31, 2025, confirms compliance with Regulation AB servicing criteria by key servicers including Midland Loan Services (master servicer), Greystone Servicing Company LLC (special servicer until March 4, 2025), and others. The asset pool consists of commercial mortgage loans, with no single obligor exceeding 10% per Item 1112(b). Notable loans include MGM Grand & Mandalay Bay (6.9% of cut-off date pool), 410 Tenth Avenue (6.9%), 141 Livingston (6.5%), Phillips Point (6.5%), and Galleria Office Towers (5.6%). Pari passu and companion loans are serviced under referenced PSAs/Exhibits 4.1-4.6. No XBRL financial statements provided; Item 8 omitted. Servicing assessments and attestations from PwC, RSM, KPMG, etc., affirm material compliance. Legal proceedings involve CWCapital Asset Management LLC (special servicer for certain loans), with resolved or dismissed cases. No material unresolved staff comments, cybersecurity disclosures, or foreign jurisdiction issues. The trust remains non-accelerated filer, no common equity market. Forward significance: Continued servicing stability supports certificateholder interests amid ongoing litigation resolutions.

The BBCMS Mortgage Trust 2020-C8 10-K filing, dated March 24, 2026, for fiscal year ended December 31, 2025, confirms full compliance with Regulation AB servicing criteria by all key servicers including Midland Loan Services (master servicer), LNR Partners (special servicer prior to March 1, 2025), Wells Fargo (special servicer/certificate administrator prior to March 1, 2025), Trimont LLC (special servicer post-March 1, 2025), and others like KeyBank and Situs Holdings. No XBRL financial data is available, and traditional financial statements are omitted per standard ABS reporting. The trust holds a pool of commercial mortgage loans, with major components including SoCal & South Miami Medical Office Portfolio (9.997% of cut-off pool), MGM Grand & Mandalay Bay (9.9%), One Manhattan West (9.997%), PGH17 Self Storage Portfolio (5.3%), and others like 9th & Thomas (3.7%) and 711 Fifth Avenue (2.9%). All servicers provided positive assessments and attestations, with no material instances of noncompliance reported. Explanatory notes detail loan combinations and servicing transfers (e.g., Wells Fargo to Trimont on March 1, 2025). No significant legal proceedings or cybersecurity issues noted. Investor focus: stable servicing structure supports ongoing trust performance amid no disclosed delinquencies or resolutions.

Eni S.p.A. filed its Annual Report on Form 20-F for the year ended 31 December 2025 with the U.S. Securities and Exchange Commission on March 24, 2026. The report is published on eni.com in the “Publications” section, and shareholders can request free hard copies via segreteriasocietaria.azionisti@eni.com or investor.relations@eni.com.

Eni S.p.A. filed its Annual Report on Form 20-F for the year ended 31 December 2025 with the U.S. Securities and Exchange Commission on March 24, 2026. The report is published on eni.com in the “Publications” section, and shareholders can request free hard copies via segreteriasocietaria.azionisti@eni.com or investor.relations@eni.com.

British American Tobacco p.l.c. disclosed notification of transactions by persons discharging managerial responsibilities: Chief Executive Tadeu Marroco transferred 90,972 ordinary shares (GB0002875804) to a joint account with Luciana Franco Do Amaral for nil consideration on 2026-03-23 outside a trading venue. Luciana Franco Do Amaral is a person closely associated with the Chief Executive.

British American Tobacco p.l.c. disclosed notification of transactions by persons discharging managerial responsibilities: Chief Executive Tadeu Marroco transferred 90,972 ordinary shares (GB0002875804) to a joint account with Luciana Franco Do Amaral for nil consideration on 2026-03-23 outside a trading venue. Luciana Franco Do Amaral is a person closely associated with the Chief Executive.

The Federal Home Loan Bank of Indianapolis has or will become the primary obligor on the settlement date for certain consolidated obligation bonds committed to be issued by the Federal Home Loan Banks, with maturities of one year or more. The bonds are fixed-rate, Bermudan-style callable Optional Principal Redemption bonds with coupons of 4.250% to 4.550% and par amounts of $10 million or $15 million each.